Ligand Pharmaceuticals (LGND) Competitors $110.43 +0.57 (+0.52%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LGND vs. EXAS, RGEN, HALO, MDGL, IONS, ALKS, FOLD, BCRX, MNKD, and DVAXShould you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. Ligand Pharmaceuticals vs. Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Ionis Pharmaceuticals Alkermes Amicus Therapeutics BioCryst Pharmaceuticals MannKind Dynavax Technologies Ligand Pharmaceuticals (NASDAQ:LGND) and Exact Sciences (NASDAQ:EXAS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking. Do analysts rate LGND or EXAS? Ligand Pharmaceuticals currently has a consensus price target of $146.43, suggesting a potential upside of 33.75%. Exact Sciences has a consensus price target of $69.25, suggesting a potential upside of 49.15%. Given Exact Sciences' higher probable upside, analysts plainly believe Exact Sciences is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 Does the media favor LGND or EXAS? In the previous week, Exact Sciences had 13 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 21 mentions for Exact Sciences and 8 mentions for Ligand Pharmaceuticals. Exact Sciences' average media sentiment score of 0.99 beat Ligand Pharmaceuticals' score of 0.98 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 12 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, LGND or EXAS? Ligand Pharmaceuticals has higher earnings, but lower revenue than Exact Sciences. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M12.63$52.15M-$0.16-684.26Exact Sciences$2.76B3.13-$204.15M-$5.57-8.34 Is LGND or EXAS more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to Exact Sciences' net margin of -37.29%. Ligand Pharmaceuticals' return on equity of 4.95% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals29.68% 4.95% 4.39% Exact Sciences -37.29%-5.29%-2.45% Do institutionals & insiders have more ownership in LGND or EXAS? 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 1.4% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, LGND or EXAS? Ligand Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Does the MarketBeat Community believe in LGND or EXAS? Exact Sciences received 438 more outperform votes than Ligand Pharmaceuticals when rated by MarketBeat users. Likewise, 73.14% of users gave Exact Sciences an outperform vote while only 70.45% of users gave Ligand Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLigand PharmaceuticalsOutperform Votes55370.45% Underperform Votes23229.55% Exact SciencesOutperform Votes99173.14% Underperform Votes36426.86% SummaryLigand Pharmaceuticals beats Exact Sciences on 10 of the 19 factors compared between the two stocks. Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGND vs. The Competition Export to ExcelMetricLigand PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio43.637.3222.5518.49Price / Sales12.63239.19394.97102.66Price / Cash24.3965.8538.1834.62Price / Book2.716.436.694.25Net Income$52.15M$143.21M$3.22B$248.31M7 Day Performance0.86%1.24%1.11%1.12%1 Month Performance4.45%6.09%3.59%3.68%1 Year Performance53.29%-3.34%15.65%5.19% Ligand Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGNDLigand Pharmaceuticals4.3875 of 5 stars$110.43+0.5%$146.43+32.6%+57.2%$2.13B$167.13M43.9480Upcoming EarningsNews CoverageEXASExact Sciences4.4898 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400RGENRepligen4.8598 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageHALOHalozyme Therapeutics3.9987 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionMDGLMadrigal Pharmaceuticals3.7383 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690Earnings ReportUpcoming EarningsNews CoveragePositive NewsIONSIonis Pharmaceuticals4.1869 of 5 stars$28.51+0.4%$56.72+99.0%-25.6%$4.53B$705.14M-9.38800Earnings ReportAnalyst ForecastNews CoverageALKSAlkermes4.2624 of 5 stars$27.00flat$38.50+42.6%+17.2%$4.45B$1.56B12.442,280Earnings ReportAnalyst ForecastNews CoverageFOLDAmicus Therapeutics4.3778 of 5 stars$6.71-1.8%$16.75+149.6%-23.1%$2.06B$528.30M-37.28480Earnings ReportNews CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.4625 of 5 stars$7.53+1.8%$15.57+106.8%+114.3%$1.57B$450.71M-12.34530Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageMNKDMannKind3.1294 of 5 stars$4.44-2.2%$9.56+115.4%+22.6%$1.35B$285.50M63.43400Upcoming EarningsPositive NewsDVAXDynavax Technologies4.2926 of 5 stars$10.44+1.3%$20.50+96.4%+3.3%$1.30B$277.25M58.00350Upcoming Earnings Related Companies and Tools Related Companies EXAS Competitors RGEN Competitors HALO Competitors MDGL Competitors IONS Competitors ALKS Competitors FOLD Competitors BCRX Competitors MNKD Competitors DVAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGND) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LGND Stock Free LGND Stock Alerts